2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/08/17Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan Orphan Drug Designation Granted by FDA for ZX008 in Lennox Gastaut Syndrome; Phase 3 Clinical Trial Expected to Begin in Fourth Quarter of 2017 Company Will Host a Conference Call Today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:Z... 
Printer Friendly Version
08/01/17Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2017, after the market close, and will host a corporate update conference call and webcast on Tuesday, August 8 at 4:30 PM Eastern Time. Tuesday, August 8th @ 4:30 PM Eastern Time/1:30 PM Pacific Ti... 
Printer Friendly Version
06/22/17Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
EMERYVILLE, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the U.S. Food & Drug Administration (FDA) has granted its investigational drug, ZX008 (low-dose fenfluramine), orphan drug designation for the treatment of Lennox Gastaut Syndrome (LGS), a refractory, debilitating childhood-onset epilepsy. The Orphan Drug Designation by the FD... 
Printer Friendly Version
05/31/17Zogenix to Present at the Jefferies 2017 Global Healthcare Conference
EMERYVILLE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY. Zogenix Presentation Details ... 
Printer Friendly Version
05/22/17Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
New Research Expands Understanding of ZX008 Mechanism in Treating Seizures EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that new data on the mechanism of action of ZX008 was presented in a poster at the 72nd Annual Meeting of the Society of Biological Psychiatry, held May 18 – 20, 2017, in San Diego, CA (see study data here)... 
Printer Friendly Version
05/04/17Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome;  Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of ZX008 in Lennox Gastaut Syndrome Company will host a conference call today at 4:30 p.m. EDT/1:30 p.m. PDT EMERYVILLE, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorde... 
Printer Friendly Version
04/27/17Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
Study 1 Top-Line Data on Track for 3Q 2017 EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the last patient has been randomized into the treatment period of Study 1, its first Phase 3 clinical trial evaluating ZX008 (low-dose fenfluramine) as an adjunctive treatment for seizures in children and young adults with Dravet s... 
Printer Friendly Version
04/27/17Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2017, after the market close, and will host a corporate update conference call and webcast on Thursday, May 4th, at 4:30 PM Eastern Time. Thursday, May 4th @ 4:30 PM Eastern Time/1:30 PM Pacific Ti... 
Printer Friendly Version
03/15/17Zogenix to Participate in the Oppenheimer 27th Annual Healthcare Conference
EMERYVILLE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will provide a corporate overview at the Oppenheimer 27th Annual Healthcare Conference, taking place March 21-22, 2017, in New York, NY.     Zoge... 
Printer Friendly Version
03/09/17Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
Top-Line Data for First Phase 3 Study Expected in 3Q 2017 ZX008 Phase 3 Pivotal Study 1504 Initiated – Target Data Readout by End of 2017 Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H 2017 Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST EMERYVILLE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorde... 
Printer Friendly Version
03/02/17Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9
EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.   Thursday, Marc... 
Printer Friendly Version
03/01/17Zogenix Receives Orphan Drug Designation in the European Union for ZX008 in Lennox Gastaut Syndrome
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that the European Commission (EC) has designated ZX008 (fenfluramine) as an orphan medicinal product for the treatment of Lennox Gastaut Syndrome (LGS), a refractory, debilitating childhood-onset epilepsy. The EC’s approval follows a positive opinion in January from the European ... 
Printer Friendly Version
02/15/17Zogenix to Participate in the 2017 RBC Capital Markets Healthcare Conference
EMERYVILLE, Calif., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will conduct investor meetings at the RBC Capital Markets Healthcare Conference, taking place February 22-23, 2017, in New York, NY. About Zogenix Zogenix, Inc. (Nasdaq:ZGNX... 
Printer Friendly Version
02/13/17Zogenix Announces Initiation of Clinical Efficacy Portion of Study 1504 for ZX008 in Dravet Syndrome
Study 1504 Part of Phase 3 Program for ZX008 in Dravet Syndrome Safety and Efficacy Portion of Study Expanded from EU to Include Sites in U.S. and Canada EMERYVILLE, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced the initiation of the clinical efficacy portion of Study 1504 for ZX008 in patients with Dravet syndrome.  Study 1504 is a... 
Printer Friendly Version
02/08/17Zogenix to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Leerink Partners 6th Annual Global Healthcare Conference in New York on February 15, 2017. Leerink Partners 6th Annual Global Healthcare Conference -- Zogenix Presentation Details Date: Wedn... 
Printer Friendly Version
01/30/17Zogenix Announces Issuance of U.S. Patent for ZX008 in Dravet Syndrome
Issued Patent is First Covering Company’s Treatment of Seizures Associated with Dravet Syndrome Using Fenfluramine as an Adjunctive Therapy EMERYVILLE, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today the recent issuance of U.S. Patent No. 9,549,909 from the U.S. Patent & Trademark Office.  The patent, entitled “Method for the Treatmen... 
Printer Friendly Version
01/05/17Zogenix Announces CFO Transition
Ann D. Rhoads to Depart Company Following Transition Period; Biopharmaceutical Industry Veteran Michael P. Smith Appointed New CFO EMERYVILLE, Calif., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that due to the Company’s ongoing relocation of all corporate functions, including finance, from San Diego, CA, to Emeryville, CA, Ann D. Rhoads, Exe... 
Printer Friendly Version